WILMINGTON, Del. / Oct 08, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024.
The schedule for the press release and conference call/webcast is as follows:
• Q3 2024 Press Release: | October 29, 2024 at 7:00 a.m. ET |
• Q3 2024 Conference Call: | October 29, 2024 at 8:00 a.m. ET |
• Domestic Dial-In Number: | 877-407-3042 |
• International Dial-In Number: | 201-389-0864 |
• Conference ID Number: | 13749146 |
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13749146.
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
| Last Trade: | US$74.62 |
| Daily Change: | 2.59 3.60 |
| Daily Volume: | 2,523,949 |
| Market Cap: | US$14.380B |
November 25, 2024 November 18, 2024 October 30, 2024 October 29, 2024 September 25, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
